Document Type

Article

Publication Date

2018

Keywords

Alzheimer's disease, betaine, vitamin B12, folate, N-acetylcysteine (NAC), reactive oxygen species (ROS), glutathione (GSH), hyperhomocysteinemia (HHcy), total homocysteine (tHcy)

Abstract

In the United States, Alzheimer's disease (AD) is the most common cause of dementia, accompanied by substantial economic and emotional costs. During 2015, more than 15 million family members who provided care to AD patients had an estimated total cost of 221 billion dollars. Recent studies have shown that elevated total plasma levels of homocysteine (tHcy), a condition known as hyperhomocysteinemia (HHcy), is a risk factor for AD. HHcy is associated with cognitive decline, brain atrophy, and dementia; enhances the vulnerability of neurons to oxidative injury; and damages the blood–brain barrier. Many therapeutic supplements containing vitamin B12 and folate have been studied to help decrease tHcy to a certain degree. However, a therapeutic cocktail approach with 5-methyltetrahydrofolate, methyl B12, betaine, and N-acetylcysteine (NAC) have not been studied. This novel approach may help target multiple pathways simultaneously to decrease tHcy and its toxicity substantially.

Digital Object Identifier (DOI)

https://doi.org/10.1177/2155179017722280

Rights Information

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License

Citation / Publisher Attribution

Cell Medicine, v. 10, p. 1-6

Was this content written or created while at USF?

Yes

Included in

Neurosurgery Commons

Share

COinS